Tech Company Financing Transactions
Agenovir Funding Round
Agenovir, based in San Francisco, scored $10.6 million in funding from Data Collective, Celgene and Lightspeed Venture Partners.
Transaction Overview
Company Name
Announced On
5/18/2016
Transaction Type
Venture Equity
Amount
$10,600,000
Round
Series A
Investors
Proceeds Purpose
With this financing led by top tier venture, corporate and individual investors, we expect to build an exceptional leadership team and accelerate our research and development programs to treat diseases associated or caused by latent or persistent viral reservoirs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7000 Shoreline Ct. 320
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Agenovir is a leader in the research and development of a novel class of human therapeutics to address diseases associated with or caused by latent or persistent viral reservoirs. The individuals affected by these diseases number in the millions, and treatment options are extremely limited or non-existent.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dirk Thye
Chief Scientific Officer
Bolyn Hubby
Founder
Stephen Quake
VP - R & D
Derek Sloan
Browse more venture capital transactions:
Prev: 5/18/2016: Scilex Pharmaceuticals venture capital transaction
Next: 5/18/2016: Capshare venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs